Disease · MONDO_0006513
estrogen-receptor negative breast cancer
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. estrogen-receptor negative breast cancer. Diseases, record MONDO_0006513. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006513
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAMOXIFEN | CHEMBL83 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPIRUBICIN | CHEMBL417 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IXABEPILONE | CHEMBL1201752 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEFLUNOMIDE | CHEMBL960 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERLOTINIB HYDROCHLORIDE | CHEMBL1079742 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 2 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1723 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| TUBA1A | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 20
See all 20 targetsTrials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00232505 | Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer | Phase 2 | 112 | 2017-06-28 | Breast Cancer | CARBOPLATIN, CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00503841 | Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer | Not applicable | 44 | 2013-02-12 | Breast Cancer | ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03011684 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | Phase 3 | 309 | Infertility | LETROZOLE, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT00751868 | FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC | Phase 2 | 47 | Breast Cancer | CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL, IXABEPILONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03709446 | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | Phase 1/2 | 17 | Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer | LEFLUNOMIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006513
GET https://conductscience.org/api/diseases/v1/MONDO_0006513/drugs